FDA Brief

Warning letters Drugs

FDA warning letter to

Maria A. Carballosa, M.D.

MediumIssued Dec 12, 2025Posted Dec 23, 2025Center for Drug Evaluation and Research (CDER)

FDA warns Dr. Maria Carballosa over failure to retain clinical trial records for an investigational drug.

What happened

FDA inspected Power MD Clinical Research Institute in Hialeah, Florida, from March 4 to 6, 2025, as part of its Bioresearch Monitoring Program. FDA found that Dr. Carballosa did not retain study-drug disposition records or adequate and accurate case histories, including signed and dated informed consent forms and case report forms, for Protocol (b)(4). She said the records may have moved with Power MD's owner but provided no evidence of FDA notification or permission, and she did not know where the records were or whether they existed.

What FDA found

  1. Failed to retain records showing the study drug's disposition, including dates, quantity, and use by subjects.

    21 CFR 312.62(c)
  2. Failed to retain adequate and accurate case histories, including signed and dated informed consent forms, case report forms, and supporting data.

    21 CFR 312.62(c)

What FDA wants

Within 15 business days, FDA asks Dr. Carballosa to notify the office in writing of actions taken to prevent similar violations and to explain how study records will be retained as required.

Who should pay attention

  • clinical investigators in FDA-regulated trials
  • sponsors relying on site records for applications
  • research sites and CROs that archive trial records

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Amy Lightner, MD

    FDA warns sponsor-investigator Amy Lightner, MD over clinical trial violations, including dosing before eligibility tests and unreported serious adverse events.

    High risk
  2. Mehran Michael Bahrami, M.D.

    FDA warns clinical investigator Dr. Mehran Michael Bahrami over protocol violations and missing records in investigational drug trials.

    High risk
  3. Konrad Rejdak, M.D., Ph.D.

    FDA warns Dr. Konrad Rejdak over clinical trial data integrity failures in a CIDP immune globulin study.

    Medium
  4. Cipla Limited

    FDA warned Cipla about unresolved albuterol inhaler delivery complaints and contamination in sterile manufacturing at its Indore site.

    High risk